Risk Factors for mortality among patients with pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Montero, Maria Milagro
- dc.contributor.author López Montesinos, Inmaculada
- dc.contributor.author Knobel Freud, Hernando
- dc.contributor.author Molas, Ema
- dc.contributor.author Sorli Redó, M. Luisa
- dc.contributor.author Siverio, Ana
- dc.contributor.author Prim, Núri
- dc.contributor.author Segura, Concepción
- dc.contributor.author Duran Jordà, Xavier, 1974-
- dc.contributor.author Grau Cerrato, Santiago
- dc.contributor.author Horcajada Gallego, Juan Pablo
- dc.date.accessioned 2021-04-27T06:20:21Z
- dc.date.available 2021-04-27T06:20:21Z
- dc.date.issued 2020
- dc.description.abstract This study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31.9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3.07, 95% confidence interval (CI), 1.73-5.46), septic shock (HR 1.75, 95% CI, 1.12-2.75), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12-1.38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0.39, 95% CI, 0.24-0.62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0.56, 95% CI, 0.33-0.93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources.
- dc.format.mimetype application/pdf
- dc.identifier.citation Montero MM, López Montesinos I, Knobel H, Molas E, Sorlí L, Siverio-Parés A, et al. Risk Factors for mortality among patients with pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?. J Clin Med. 2020 Feb 14; 9(2): 514. DOI: 10.3390/jcm9020514
- dc.identifier.doi http://dx.doi.org/10.3390/jcm9020514
- dc.identifier.issn 2077-0383
- dc.identifier.uri http://hdl.handle.net/10230/47212
- dc.language.iso eng
- dc.publisher MDPI
- dc.rights Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Bacteremia
- dc.subject.keyword Combined antimicrobial therapy;
- dc.subject.keyword Extensively drug-resistant Pseudomonas aeruginosa
- dc.subject.keyword High-risk clones
- dc.subject.keyword Multidrug resistance
- dc.subject.keyword Outcome
- dc.title Risk Factors for mortality among patients with pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion